Combination of HD + HP can increase clearance of uremic toxin molecules more
effectively as compared to conventional HD, resulting in prevention of short term and
long term complication in regular hemodialysis patients. The result of this trial shows the
combination of HD + HP decreases β2-microglobulin serum concentration and improved
patient’s quality of life, using SF-36 score. Combination of HD + HP does not affect the
result of hope for life on regular hemodialysis patients, as shown from the BIA phase
angle result. Decrease in β2-microglobulin concentration is negatively correlated with
mental health dimension. Combination of HD + JP also rapidly improved subjective
complains such as lack of appetite, body pain, itchiness and lack of sleep. Combination
of HD + HP is biocompatible, hence, it is safe for use on regular HD patients. As proven
during this trial, there are no side effects.